Today: 9 June 2026
XRP Price Today: Ripple Korea Bond Deal Lifts Token Near $1.39, but Rakuten Delay Caps Gains
15 April 2026
1 min read

XRP Price Today: Ripple Korea Bond Deal Lifts Token Near $1.39, but Rakuten Delay Caps Gains

NEW YORK, April 15, 2026, 15:00 EDT

XRP was changing hands at about $1.38 to $1.39 on Wednesday, following Ripple’s announcement of a new partnership with South Korea’s Kyobo Life Insurance for blockchain-powered government bond settlements. The token got a shot of institutional credibility from the news. Still, any upside was checked after Japan’s Rakuten Wallet pushed back its April 15 launch for XRP and four other coins.

These headlines hit home for XRP, which remains far off its highs from last year. Traders are watching for actual adoption, not just more legal news or regulatory updates. Ripple has announced the Kyobo project’s focus: piloting tokenized government bonds, or bonds turned into blockchain-based digital assets. The company says settlement for these bonds could drop from the standard two days to almost instantly.

XRP traded between $1.38 and $1.39 on CoinMarketCap and CoinGecko, showing gains of roughly 1.4% to 2.2% in the past 24 hours. Turnover hit about $2.5 billion, with market cap sitting close to $85 billion. Bitcoin hovered near $74,340, while ether was quoted at $2,356—XRP moving in line with the broader crypto space.

Ripple is calling this its first partnership with a major Korean insurer, adding that settlement will run through Ripple Custody, the company’s own digital asset safekeeping platform. “Institutional-grade digital asset infrastructure is no longer a future aspiration,” said Fiona Murray, Ripple’s managing director for Asia Pacific. For Kyobo, executive vice president Jin Ho Park said the project’s goal is to test whether blockchain can handle traditional instruments “securely and efficiently.” Ripple

Japan factored in too. On April 7, Rakuten Wallet announced plans to add XRP and four other tokens starting April 15. That timeline changed—on Wednesday, the company posted that the launch of all five tokens was postponed.

XRP now faces a different setup from last year. Back in March 2025, Reuters said the U.S. Securities and Exchange Commission dropped its appeal of a 2023 decision that found XRP sales on public exchanges weren’t securities. That same month, Franklin Templeton put in for an XRP ETF, while CME followed a few weeks later, rolling out XRP futures and pushing the token further into mainstream investment territory.

Crypto sentiment remains patchy. On Tuesday, Reuters noted that Goldman Sachs has filed for its debut bitcoin ETF, though Morningstar’s Bryan Armour described such an offering as “a hard sell” given the market’s volatility. The UK’s Financial Conduct Authority, meanwhile, kicked off a consultation on fresh crypto rules the following day. Reuters

XRP’s vulnerabilities stand out. The token is still trading roughly 62% under its $3.65 all-time high, according to CoinGecko. Fresh headlines aren’t a substitute for sticky demand: if the Korean bond settlement doesn’t move beyond a pilot phase and Rakuten’s hold-up stretches on, Wednesday’s pop may prove short-lived.

Stock Market Today

  • SailPoint Q1 Earnings Beat Estimates Amid Revenue Growth
    June 9, 2026, 10:14 AM EDT. SailPoint, Inc. (SAIL) reported Q1 earnings of $0.05 per share, surpassing the Zacks Consensus Estimate of $0.04 by 17.65%. Revenue increased to $280.14 million, beating estimates by 1.41% and up from $230.47 million a year ago. Despite earnings surprises and revenue growth, SailPoint shares have declined 12.6% year-to-date against the S&P 500's 8.2% rise. The company holds a Zacks Rank #3 (Hold), indicating expected market-aligned performance. Consensus estimates forecast Q2 EPS of $0.08 on $310.79 million revenue and fiscal year EPS of $0.32 on $1.27 billion revenue. Industry trends in the Zacks Internet-Software sector will influence future stock performance. Investors await management's commentary for guidance on sustainability.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Super Micro Computer Launches Edge AI Servers as SMCI Faces Margin and Compliance Test
Previous Story

Super Micro Computer Launches Edge AI Servers as SMCI Faces Margin and Compliance Test

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama
Next Story

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Go toTop